Claims
- 1) A compound of formula I:
- 2) A compound of claim 1 wherein Z is a radical of formula II or III.
- 3) A compound of claim 1 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms; R2 is hydrogen, trifluoromethyl, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms, or alkyl of one to six carbon atoms and Z is a radical of formula II.
- 4) A compound of claim 3 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms and R2 is hydrogen, trifluoromethyl or alkyl of one to six carbon atoms.
- 5) A compound of claim 1 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms; R2 is hydrogen, trifluoromethyl, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms, or alkyl of one to six carbon atoms; Z is a radical of formula III, R4 is hydroxy and R5 is Ar.
- 6) A compound of claim 5 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms and R2 is hydrogen, trifluoromethyl or alkyl of one to six carbon atoms.
- 7) A compound of claim 1 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms; R2 is hydrogen, trifluoromethyl, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms, or alkyl of one to six carbon atom; Z is a radical of formula III, R4 is hydrogen and R5 is benzoyl, 1-benzimidazol-2-one, benzoisothiazole, or benzisoxazole, each optionally substituted, or —(CH2)mQ.
- 8) A compound of claim 7 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms; R2 is hydrogen, trifluoromethyl or alkyl of one to six carbon atoms, and m is 0 or 1.
- 9) The compound of claim 1 which is 8-(2-methyl-7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-8-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one or a pharmaceutically acceptable salt thereof.
- 10) The compound of claim 1 which is 1-[1-(2-methyl-7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-8-ylmethyl)-piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 11) The compound of claim 1 which is 1-(2-methyl-7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-8-ylmethyl)-4-[3-(trifluoromethyl)phenyl]-4-piperidinol or a pharmaceutically acceptable salt thereof.
- 12) The compound of claim 1 which is (4-fluorophenyl)(1-[2-methyl-7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-8-ylmethyl]-4-piperidinyl)methanone or a pharmaceutically acceptable salt thereof.
- 13) The compound of claim 1 which is 2-methyl-8-{[4-(3-trifluoromethyl)phenyl-3,6-dihydro-1(2H)-pyridinyl]methyl}-7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalene or a pharmaceutically acceptable salt thereof.
- 14) The compound of claim 1 which is 2-methyl-8-(piperidin-1-ylmethyl)-7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene or a pharmaceutically acceptable salt thereof.
- 15) A method of treating a subject suffering from a condition selected from the group consisting of cognitive deficits, neurodegenerative disease, or schizophrenia which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I:
- 16) The method of claim 15 wherein the subject is a human.
- 17) A method of treating a subject suffering from a condition selected from the group consisting of anxiety, aggression and stress which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 18) The method of claim 17 wherein the subject is a human.
- 19) A method of treating a subject suffering from a condition selected from the group consisting of eating disorders, disorders of thermoregulation, sleep dysfunction and sexual dysfunction which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I:
- 20) The method of claim 19 wherein the subject is a human.
- 21) A method of treating a subject suffering depression comprising providing to the subject suffering from said condition, an antidepressant amount of a serotonin selective reuptake inhibitor and an amount of a compound of formula I:
- 22) The method of claim 21 wherein the subject is a human.
- 23) The method of claim 21 wherein the serotonin selective reuptake inhibitor is sertraline, fluvoxamine, paroxetine, venlafaxine, duloxetine, citalopram, fluoxetine or metabolites thereof.
- 24) A pharmaceutical composition comprising a compound of formula I:
- 25) The composition of claim 24 further comprising an antidepressant amount of a serotonin selective reuptake inhibitor.
- 26) The composition of claim 25 wherein the serotonin selective reuptake inhibitor is sertraline, fluvoxamine, paroxetine, venlafaxine, duloxetine, citalopram, fluoxetine or metabolites thereof.
Parent Case Info
[0001] This application claims priority from co-pending provisional application serial No. 60/289,168, filed on May 7, 2001 ,the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60289168 |
May 2001 |
US |